A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants
2021年6月16日 更新者：UCB Biopharma S.P.R.L.
An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants
The purpose of the study is to investigate the pharmacokinetics (PK) of padesevonil in CYP2C19 genotyped healthy male Japanese study participants.
調査の概要
研究の種類
介入
入学 (実際)
39
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
-
Tokyo、日本
- Up0083 001
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
20年～55年 (大人)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
男
説明
Inclusion Criteria:
- The study participant must be 20 to 55 years of age inclusive, at the time of signing the informed consent
- The study participant is overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
- The study participant is of Japanese descent as evidenced by appearance and verbal confirmation of familial heritage
- The study participant has a body weight ≥50 kg and body mass index within the range [18 to 30] kg/m^2 (inclusive)
- The study participant is male
Exclusion Criteria:
- The study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study, such as a history of schizophrenia, or other psychotic disorder, bipolar disorder, or severe unipolar depression. The presence of potential psychiatric exclusion criteria will be determined based on the psychiatric history collected at the Screening Visit
- The study participant has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
- The study participant has a history of unexplained syncope or a family history of sudden death due to long QT syndrome
- The study participant has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Screening/Baseline" version of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening
- The study participant has alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >1.0 x upper limit of normal (ULN)
- The study participant has bilirubin >1.0 x ULN (isolated bilirubin >1.0 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 %)
- The study participant has current or chronic history of liver disease or known hepatic or biliary abnormalities
- The study participant has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline.
- The study participant has made a blood or plasma donation or has had a comparable blood loss (>450 mL) within the last 30 days prior to Screening. Blood donation during the study is not permitted
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：基礎科学
- 割り当て：非ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Extensive metabolizers
Participants will receive assigned single and multiple doses of padsevonil.
|
パドセボニルは、事前定義された用量で投与されます。
|
|
実験的：Intermediate metabolizers
Participants will receive assigned single and multiple doses of padsevonil.
|
パドセボニルは、事前定義された用量で投与されます。
|
|
実験的：Poor metabolizers
Participants will receive assigned single and multiple doses of padsevonil.
|
パドセボニルは、事前定義された用量で投与されます。
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil
時間枠：Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
Cmax is the maximum plasma drug concentration of PSL observed from pharmacokinetic samples taken at predefined time points.
|
Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
|
Area Under the Curve From 0 to t (AUC(0-t)) of a Single Dose Padsevonil
時間枠：Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
AUC(0-t) is the area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration.
|
Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
|
Area Under the Curve From Time 0 to Infinity (AUC) of a Single Dose Padsevonil
時間枠：Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
AUC is the area under the plasma concentration-time curve from time zero to infinity.
|
Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
|
Terminal Half-life (t1/2) of a Single Dose Padsevonil
時間枠：Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
The t1/2 is the apparent terminal half-life.
Geometric Means and Geometric Coefficient of Variations were only calculated if at least 2/3 of the parameters were properly determined parameters (i.e.
non-calculated and non-flagged).
|
Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
|
Time to Reach the Maximum Plasma Concentration (Tmax) of a Single Dose Padsevonil
時間枠：Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
The tmax is the time to reach maximum plasma concentration.
|
Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours postdose (up to Day 3)
|
|
Maximum Plasma Concentration (Cmax) of Padsevonil at Steady-state (ss)
時間枠：Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
Cmax, ss is the maximum plasma concentration of PSL observed from pharmacokinetic samples, taken at predefined time point at a steady-state.
|
Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
|
Area Under the Curve Over a Dosing Interval (AUCtau) of Multiple Doses Padsevonil
時間枠：Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
AUCtau is the area under the plasma concentration time curve over a dosing interval.
|
Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
|
Terminal Half-life (t1/2) of Multiple Doses Padsevonil
時間枠：Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
The t1/2 is the apparent terminal half-life.
|
Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
|
Time to Reach Maximum Concentration (Tmax) for Padsevonil at Steady-state (ss)
時間枠：Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
The tmax, ss is the time of observed maximum plasma concentration at a steady-state.
|
Day 10: Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after the morning dose
|
|
Percentage of Participants With Treatment Emergent Adverse Events During the Study
時間枠：From Baseline until the Safety Follow-up Visit (up to Day 21)
|
An Adverse Event (AE) is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device.
The event does not necessarily have a causal relationship with that treatment or usage.
|
From Baseline until the Safety Follow-up Visit (up to Day 21)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2019年9月30日
一次修了 (実際)
2019年12月27日
研究の完了 (実際)
2019年12月27日
試験登録日
最初に提出
2019年8月29日
QC基準を満たした最初の提出物
2019年8月29日
最初の投稿 (実際)
2019年8月30日
学習記録の更新
投稿された最後の更新 (実際)
2021年7月8日
QC基準を満たした最後の更新が送信されました
2021年6月16日
最終確認日
2021年6月1日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
IPD プランの説明
Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified.
For this reason, data from this trial cannot be shared.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。